Research work · 2016

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle

The Lancet

Download PDF

DOI: 10.1016/s0140-6736(16)32453-9